** WARNING, Not error free yet, under construction: check result to a standard work. **

START

From MedicaWiki
Jump to: navigation, search
[checked revision][checked revision]
Line 1: Line 1:
 
 
 
* [[Special:RunQuery/QueryMed|Choosing Medication in Caution Areas]]
 
* [[Special:RunQuery/QueryMed|Choosing Medication in Caution Areas]]
 
* [[Special:RunQuery/CalcBenzo|Benzodiazepine discontinuation scheme]]
 
* [[Special:RunQuery/CalcBenzo|Benzodiazepine discontinuation scheme]]
Line 11: Line 9:
  
  
{{#customtitle: Introduction | Introduction }}
+
{{#customtitle: START | Introduction }}
 
   
 
   
 
At MedicaWiki we're developing tools to improve accessibility of the abundantly available (though often scattered) information about medication.   
 
At MedicaWiki we're developing tools to improve accessibility of the abundantly available (though often scattered) information about medication.   

Revision as of 10:06, 14 July 2010





At MedicaWiki we're developing tools to improve accessibility of the abundantly available (though often scattered) information about medication.

For now we have put together monographies on antipsychotics, antidepressants, mood stabilizers and benzodiazepines. A 'monography' in this respect consists of key information for a single (generic) drug. Adverse effects, contra-indications and interactions have been combined into a number of 'caution-area's' and were scaled from 1 (safe) to 10 (unacceptable dangerous). Both scaling method itself and the assigned level need to be well-documented. A zero (0) is assigned to (yet) unscaled (and thus unknown risk) caution area's.

Documentation in this context is to be achieved by means of references to authoritative sources like Pubmed or publicly accessible monography collections. Scaling methodology will be explained at the linked page for the caution area or 'property'. Whenever possible, the scaling methodology will be mimicked from existing schemes like the schemes for pregnancy, lactation etc, rescaled to a '1-10' -scale.